Cite
HARVARD Citation
Evon, D. et al. (2022). Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. Journal of viral hepatitis. 29 (9), pp. 795-806. [Online].